ERBB2 and breast cancer: In this study, we used multiple models of human HER2–expressing tumors—i.e., KPL-4, NIH/3T3-HER2, SKOV3, MM3MG-HER2Δ16, BT-474, and an endogenous transgenic HER2+ BC model that is tolerant to human HER2.